Drug Profile

Morcamilast- Meiji Seika Pharma

Alternative Names: ME-3183

Latest Information Update: 29 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Meiji Seika Pharma
Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Palmoplantar pustulosis
New Molecular Entity Yes
Available For Licensing Yes - Palmoplantar pustulosis

Highest Development Phases

Phase II Plaque psoriasis
Phase I Palmoplantar pustulosis

Most Recent Events

31 May 2026 Phase-I clinical trials in Palmoplantar pustulosis (PO)
03 Mar 2026 Investigation in Autoimmune disorders in Japan (PO)
03 Mar 2026 Morcamilast- Meiji Seika Pharma is available for licensing as of 03 Mar 2026. www.meiji.com

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com